STROMAL DERIVED FACTOR INHIBITION AND CXCR4 BLOCKADE

• US 20190322633A1
• Filed: 07/03/2019
• Published: 10/24/2019
• Est. Priority Date: 02/17/2011
• Status: Abandoned Application

• Current Assignee: Theodore A. Blaine
• Original Assignee: Rhode Island Hospital
• Inventors: Blaine, Theodore A.
• Application Number:
  US16/502,693
• Publication Number:
  US 20190322633A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/497 containing further heterocyclic rings
• CPC Class Codes: A61K 38/10 Peptides having 12 to 20 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: C07C 211/27 having amino groups linked to the six-membered aromatic ring by saturated carbon chains
• CPC Class Codes: C07C 237/30 having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
• CPC Class Codes: C07C 257/18 having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
• CPC Class Codes: C07D 233/64 with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• CPC Class Codes: C07D 233/88 Nitrogen atoms, e.g. allantoin
• CPC Class Codes: C07D 295/135 with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Abstract

The invention relates to inhibition of SDF-1α expression in subacromial bursa cells by CXCR-4 inhibitors. Bursal cell migration in response to SDF-α stimulation is also decreased in the presence of CXCR4 inhibitors. Accordingly, provided are methods for treating or ameliorating a musculoskeletal disorder.

Claims

1. A method for treating a tendon injury in a subject, comprising administering to said subject a compound that binds to CXCR4,

wherein said compound is a peptide inhibitor, and wherein said peptide inhibitor comprises a sequence of SEQ ID NO:

7, 8, or 9, thereby treating said tendon injury,

wherein said tendon injury comprises a tendon rupture or tear, wherein said tendon comprises an Achilles tendon, an elbow tendon, a patellar tendon, a finger flexor or extensor tendon, or a toe digital flexor or extensor tendon.

2. The method of claim 1, wherein said compound is administered locally to a musculoskeletal tissue, said tissue comprising the rupture or tear.

18. The method of claim 1, wherein treating said tendon injury comprises healing the tendon.

19. The method of claim 1, wherein treating said tendon injury comprises reducing inflammation.

20. The method of claim 1, wherein said tendon injury comprises a tendon rupture.

21. The method of claim 1, wherein said tendon injury comprises a tendon tear.

22. The method of claim 1, wherein the tendon comprises an Achilles ten-don.

23. The method of claim 1, wherein the tendon comprises an elbow tendon or a patellar tendon.

24. The method of claim 1, wherein the tendon comprises a finger flexor or extensor tendon or a toe digital flexor or extensor tendon.

3-17. -17. (canceled)